Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? [Yahoo! Finance]
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at JPMorgan Chase & Co. from $20.00 to $25.00. They now have a "neutral" rating on the stock.
Compass Therapeutics Announces Key Leadership Appointments [Yahoo! Finance]
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026